# Illumina (ILMN) Q3 FY2026 earnings

Results filed 2026-10-29 for the quarter ended 2026-09-27. Source page: https://earnings.opennash.com/companies/ilmn/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000202/0001110803-26-000202-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Illumina is pairing strong NovaSeq X placements and clinical sequencing demand with a push into AI-ready biology data via its Billion Cell Atlas, now over halfway complete.

Clinical sequencing demand and NovaSeq X placements drove the quarter, with over 80 instruments placed. Clinical consumables grew 14 % in the rest of the world, while research and applied consumables kept shrinking. Several of the largest clinical customers placed multi-unit capacity orders. Illumina also launched the BioInsight analysis platform with a new splicing AI model. GSK joined the Billion Cell Atlas Consortium, and interest in leases is rising among research and mid-size clinical labs.
Management is steering Illumina from a sequencing vendor toward a supplier of multi-omics data, software and AI models for predictive biology. It expects the Billion Cell Atlas and new products to add one to two points of growth, with more visibility in 2027. Policy risk in China also remains.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $1.13 billion | up 4.2% from Q3 2025 | GAAP |
| Net income | $220 | up from $150 in Q3 2025 | GAAP |
| Diluted EPS | $1.43 | up from $0.98 in Q3 2025 | GAAP |
| Diluted EPS excluding tariff refunds | $1.44 | up from $1.34 in Q3 2025 | non-GAAP |
| Gross margin | 73.5% | up from 67.6% in Q3 2025 | GAAP |
| Operating profit | $305 | up from $227 in Q3 2025 | GAAP |
| Operating margin | 27.0% |  | GAAP |
| Operating cash flow | $419 million | compared to $284 million in the prior year period |  |
| Free cash flow | $378 million | compared to $253 million in the prior year period | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Sequencing consumables | $792 million | up 6% year-over-year |
| Sequencing instruments | $106 million | down 2 % year-over-year on a rest-of-world organic basis |
| Sequencing service and other | $158 million | up 8 % on a rest-of-world organic basis |
| Microarrays and other | $110 million | up 2 % on a rest-of-world organic basis |
| NovaSeq X placements | over 80 instruments | approximately 360 over the last four quarters |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue | fourth quarter of 2026 | $1.22 to $1.24 billion |
| Non-GAAP diluted EPS | fourth quarter of 2026 | $1.51 to $1.56 |
| Operating margin | fourth quarter of 2026 | approximately 25% |
| Total revenue excluding tariff refunds | fiscal year 2026 | $4.64-$4.66 billion |
| Non-GAAP operating margin | fiscal year 2026 | 23.6% |
| Non-GAAP diluted EPS | fiscal year 2026 | $5.40-$5.45 |

## Key takeaways

1. **NovaSeq X placements outpace the first launch year** Illumina placed over 80 instruments in the quarter, about 360 over four quarters, more than in the X's first year. Several large clinical customers ordered multiple units, which builds the installed base that drives consumables.
2. **Clinical sequencing is the main demand engine** Clinical consumables grew 14 % in the rest of the world, while research and applied fell 6 %. Management points to more sequencing-intense assays and new tests reaching the market.
3. **The NovaSeq X transition is nearly complete** Research and applied customers are at 90 % or more volume on the X, and clinical is at 78 %. Management expects lower transition pricing headwinds in 2027 and will drop the conversion slide after Q4-2026.
4. **Billion Cell Atlas anchors Illumina's AI-biology push** The atlas is over halfway complete, GSK has joined the consortium, and other biopharma companies want access. Management sees AI-ready perturbation data as a large long-term opportunity beyond selling sequencers.
5. **BioInsight bundles software, AI models and data** The new platform brings analysis applications, AI models and curated data together, including SpliceAI2. Management expects new products and BioInsight to add one to two points of growth, with more visibility in 2027.

## Analyst Q&A

- [0:19:26] Tycho Peterson, Jefferies: Were there any stocking orders in clinical, and is the implied Q4 clinical growth the right jumping-off point for next year? Answer: Management said Q3 looked like Q2 with 14-15 % clinical growth and mid-teens for the year, and that Q4 consumables expectations rose on strong placements.
- [0:21:09] Vijay Kumar, Evercore ISI: What is the right 2027 framework, are the long-range targets intact, and could instruments become a headwind? Answer: Management will give full 2027 guidance on the Q4 call, but sees clinical as a lasting growth driver, multi-omics and AI as added opportunities, and elevated X placements continuing to support growth.
- [0:23:28] Doug Shenko, UBS: Is the NovaSeq X placement strength a pull-forward, and how does demand split between capacity expansion and replacements? Answer: Management saw no pull-forward and attributed demand to a healthy clinical market, sequencing-intensive new assays and customer confidence in the X platform's innovation.
- [0:25:55] Tuneet Souda, Learink: Are new instruments driving lower cost per gigabase and elasticity, and is the high single-digit 2027 framework intact? Answer: The CEO said the X transition lowered price but raised volume as customers build bigger assays, and that Illumina remains on track for high single-digit growth in 2027.
- [0:29:13] Sabu Nandi, Guggenheim: Can new products still add one to two points of growth in 2027, and is a 25% exit operating margin the right launch point? Answer: Management said the new-asset and data growth driver is playing out, including multi-omics and SomaLogic, and that margins are up 400 basis points, with more to come.
- [0:31:24] Luke Sergot, Darkleys: How does clinical sequencing play out as liquid biopsy players grow and convert to the X? Answer: The CEO pointed to the razor-blade model, in which each X placed generates future consumables, and said clinical remains strong with many applications still coming online.
- [0:34:04] Dal Narias, SIPO: Does cheaper genome pricing force Illumina to revisit price elasticity to win large AI and virtual-cell projects? Answer: The CEO said AI opportunity goes well beyond whole-genome pricing, since Illumina can build multi-omic datasets across genome, transcriptome, methylome and proteome, and it is comfortable with elasticity.
- [0:37:04] Dave Westenberg, Piper Sandler: How fast can clinical grow and what discounting should be expected from large customers in 2027-2029? Answer: Management said customers are building bigger assays for therapy selection, MRD and MCED, that Illumina grows with them, and that US clinical growth is well above 14 %.
- [0:40:26] Kyle Mixon, Canaccord Genuity: Is there upside to the high single-digit growth target, possibly toward double digits with margins in the high 20s? Answer: The CEO said upside is not impossible given clinical, multi-omics, research recovery and AI, but Illumina wants to first show high single-digit growth.
- [0:42:39] Dan Lennon, RBC: When will BioInsight become visible in the P&L? Answer: Management expects some visibility in 2027, led by the Billion Cell Atlas, and said new products and BioInsight should add one to two points of growth.
- [0:45:11] Casey Woodring, JPMorgan: How much does the extra Q4 week add, is a budget flush expected, and has anything changed with China? Answer: The extra week falls over the holidays with minimal revenue impact, no budget flush is assumed, and Illumina is pleased to be back to growth in China while it assesses new trade restrictions on competitors.
- [0:48:27] Dan Brennan, TD Cowen: Is the AI opportunity mainly services or instrument placements, and what was NovaSeq X pricing in the quarter? Answer: Management expects a blend, with a large service opportunity in generating standardized datasets plus instrument demand from customers who want to add their own data, and the Billion Cell Atlas spans multi-omic combinations.
- [0:52:23] Dave Westenberg, Piper Sandler: What drove China growth in the quarter and how should China be viewed going forward? Answer: The CEO said Illumina is committed to China, focused on supporting customers and innovation, and sees a big opportunity there.
- [0:53:18] Tysha Peterson, Jefferies: Is the rise in operating lease interest limited to research, or could it spread to clinical? Answer: Lease and reagent rental demand is growing in research and in mid-size clinical labs, though not among the largest clinical customers who are expanding capacity.

## Questions

**What is Illumina's Billion Cell Atlas and why does it matter?** It is an AI-ready perturbation dataset, now over halfway complete, built with biopharma partners to link genetic signals to cellular mechanisms. GSK is the latest to join the consortium, and other companies are asking for access.
**How strong is NovaSeq X demand?** Illumina placed over 80 instruments in the quarter and about 360 over four quarters, more than in the X's first year. Management said there was no pull-forward and cited several multi-unit orders from large clinical customers.
**Where is sequencing demand growing and where is it shrinking?** Rest-of-world clinical consumables grew 14 %, while research and applied consumables fell 6 %. Management still expects mid-teens clinical growth and mid-to-high single-digit research and applied declines for 2026.
**Is the NovaSeq X transition finished, and what does it mean for pricing?** Research and applied customers are at 90 % or more volume on the X, and clinical is at 78 %, with 80 to 85 % expected in the coming quarters. Management therefore expects lower year-over-year transition pricing headwinds in 2027 than in 2026.
**What did Illumina launch in software and AI, and what does management expect from it?** It launched the BioInsight platform, which combines analysis applications, AI models and curated data, including the SpliceAI2 model. Management expects new products and BioInsight to add one to two points of growth, with visibility in 2027.

## Transcript

Machine-generated from https://www.youtube.com/watch?v=RXluytUqB7o


**Operator** [0:00:00]
Good day, ladies and gentlemen. Welcome to the third quarter 2026 Illumina earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, we will conduct a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the call over to Head of Investor Relations, Conor McNamara.

**Conor McNamara (Investor Relations)** [0:00:23]
Hello, everyone, and welcome to Illumina's third quarter 2026 earnings call. Today, we will review our financial results, release after the market close, and provide prepared remarks before opening the line for Q &A.
Our earnings release is available in the Investor Relations section of Illumina .com. Joining me today are Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer. Jacob will begin with an update on Illumina's business, followed by Ankur's review of our financials. As you may have seen in our press release, we recognized certain tariff refunds in the third quarter, which had a positive impact on GAAP and non-GAAP operating income, margins, and EPS, and a negative impact on revenue.
These refunds were not contemplated into our previous guidance, and all financial measures discussed today will be on an adjusted non-GAAP basis, excluding the impact of tariff refunds. Reconciliations to Nongap and GAAP can be found in today's release and in the supplementary data on our website. All revenue and revenue growth rates are presented excluding tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions, and rest of world organic growth further excludes our greater China region.
This call is being recorded, and the replay will be available on our website. As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Illumina's future events, product outlook, and financial expectations. Actual results may differ of material. Better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Illumina files with the SEC, including our most recent forms 10Q and 10K. With that, I will now turn the call over to Jacob.

**Jacob Thaysen (CEO)** [0:02:15]
Thank you, Connor, and good afternoon, everyone. We had a great third quarter with strong clinical sequencing demand and elevated NoSeqX placements, driving revenue, margin, and EPS above our guidance range. Our strategy is working, and I'm proud of what our team delivered for our customers and shareholders. Our continued disciplined execution and business momentum allow us to raise our fiscal year guidance and we remain on track to achieve our long-range financial targets. Before I go into details on our results, I want to highlight a few ways our innovation is helping customers answer new questions about biology.
Early in 2026, we introduced the Billion Cell Atlas to address one of the biggest bottlenecks in applying AI to biology – the lack of functional datasets. AI models need a large amount of data to learn from. And in biology, those models only work if the data is accurate, standardized, and reproducible. But these datasets don't exist at scale. There is no internet authority. Our billion-cell atlas was designed to help address these limitations. Now, over halfway complete, the atlas is advancing toward an unprecedented AI-ready perturbation data set that helps biopharma partners connect genetic signals to cellular mechanisms, strengthening training target validation, improve disease understanding and enable accelerated drug discovery.
By working directly with BioPharmac, we are integrating their input to ensure that proprietary dataset is relevant and built to maximize value for both our partners and Illumina. GSK is the latest biopharmaceutical company to join the BillionCell Atlas Consortium to accelerate block discovery and we are seeing growing interest from other companies seeking access to the completed atlas. We've learned a lot from our partners about how to build these datasets for AI and we see multiple opportunities to address additional bug necks across block discovery and development.
We see this as a large long-term opportunity and look forward to sharing more about our strategy in the coming quarters. Earlier this month at AFSC, we brought together our assays, sequencing platforms and software to show how customers can benefit using the Illumina Insight ecosystem. The most compelling examples came from customers themselves, who showed how combining genomics, transcriptomics, methylation, and proteomics is helping them see biology they could not see before with work spanning both single-cell and spatial approaches.
What is resonating with customers is that we are looking at their work from start to finish, making it easier to obtain all the components they need to drive high-quality insights by bringing down the total cost of the workflow. On the analysis side, we launched the BioInsight platform, which brings our analysis application AI models and curated biological data together in one place, producing the need for customers to assemble and manage separate software tools. Through the platform, customers can also access Splice AI2, our new AI model that predicts how genetic changes affect RNA splicing.
In rare disease research datasets, it identified 17 % more disease-relevant splice variants than other splicing models. I am proud of the innovation our teams continue to deliver. Our view is that the next era of life sciences innovation will be powered not only by sequencing, but also by the software, AI, and differentiated data that unlock the power of the genome. Through BionSight, Illumina is building the base for AI biology, enabling more powerful foundational models and virtual cell models with the potential to improve our ability to understand and predict biology.
As we move nearer to predicting biology, we see a path to using those insights to move healthcare toward a more proactive future, identifying risk sooner, preventing disease where possible, and intervening earlier. Now let me expand on our financial results, starting with our performance in the quarter. Costs and demand for the NovoSikX platform remains at very high levels. In the quarter, we placed over 80 instruments. This equates to approximately 360 X placements over the last four quarters, more than in our first year of launch.
This demand is being fueled by broader adoption of sequencing-based diagnostics and more sequencing-intense assays. As these instruments go live, they will support additional consumables revenue for years to come. End market growth rates for rest-of-world sequencing consumables were similar in Q3 and Q2, with clinical growth of 14 % and research and applied declines of 6%. We continue to expect mid-teens clinical growth and mid-to-high single-digital declines in research and applied sequencing consumables for rest-of-world for 2026.
Let me now turn to our outlook for the rest of the year. We are raising our full year revenue outlook to reflect Q3, up performance and a stronger Q4, driven by an increase in sequencing consumable revenue on a larger NovoSeq X installed base. We are also raising our full year margin and EPS outlooks and now expect operating margins of approximately 25 % in the second half of 2026, up about 400 basis points versus 2024. I'm extremely proud of how our teams have managed investment through a challenging environment.
With each quarter that passes, it becomes more clear our strategy is working. We are achieving what we set out to do in 2024 and capitalizing on emerging opportunities to drive growth for the years to come. I want to thank our teams for their hard work and commitment to Illumina and our customers for the trust they place in us. I look forward to sharing our 2027 guidance during the fourth quarter trainings call. And with that, I'll turn it over to Ankur to walk through our results and updated outlook.

**Ankur Dhingra (CFO)** [0:09:48]
Thank you, Jacob. and good afternoon everyone. I will walk through our third quarter financial results, provide additional color on revenue, earnings, and cash flow, and then discuss our updated outlook. As Conrad mentioned earlier, all of our financial metrics will be on a non-GAAP basis, excluding tariff refunds. The reconciliations are provided in our financial disclosures. On a high level, our Q3 revenue and earnings came in ahead of our expectations and guidance. Lesser World Organic Revenue grew 5%, Operating Margin was 25%, 100 basis points above our guidance, and Diluted EPS of $1.44 grew 7 % year over year.
Now turning to the details. During the third quarter, Illumina's revenue was $1.17 billion, dollars up 4.7 percent year-over-year on a rest-of-world organic basis with currency and acquired revenue together contributing just under three percentage points to our reported growth sequencing consumables revenue of $792 million was up 6% year-over-year and up 5% on an organic rest-of-world basis high throughput volume drove most of the revenue growth as the NovaSeekX install base continues to expand and clinical customers continue to bring their instruments online.
Sales in clinical markets grew 14 % on the rest of the world and we continue to expect mid-teens growth for clinical consumables in 2026. Sequencing consumable sales in research and applied markets declined 6 % for the rest of the world. and year-to-date trends have remained consistent with our outlook entering the year. Revenue has grown sequentially each of the last two quarters and we are seeing signs research activity is stabilizing. We continue to expect mid to high single digit declines for research and applied consumables in 2026.
Moving to the NovaSeek X transition, approximately 84 % of high throughput volume and 60 % of revenue is now on the X. In research and applied markets, 90 % or greater volume has been on the X for each of the last five quarters, signaling the conversion to X is largely complete. Thus, we expect minimal transition pricing headwinds from these customers going forward. In clinical, 78 % of volume is currently on the X and we have seen the pace of conversion slow in recent quarters.
This is the dynamic you've heard us talk about. Certain clinical customers are keeping current on-market assays on the 6k while adding X capacity for new tests. We anticipate clinical conversion to reach 80 to 85 % in the coming quarters and as such we expect the year-over-year pricing headwinds from the X transition to be lower in 2027 than in 2026. As the X conversion is nearly complete, we believe these charts are becoming less relevant in showing the price and volume dynamics impacting our revenue growth.
As such, we plan to discontinue showing this slide in our quarterly earnings presentations after Q4-2026. As it relates to sequencing activity, gigabyte base output growth on our connected high and mid-throughput instruments remained above 30%, showing that demand remained strong. Sequencing instruments revenue of $106 million was down 2 % year-over-year in Q3 on a rest-of-world organic basis. Higher NovaSeq X placements were offered by Vitape instrument sales in our Europe, Middle East, Latin America region.
X placements were up year over year in both clinical and research markets. Instrument sales still account for over 90 % of our X placements, though we are seeing an increasing level of interest in lease type arrangements with certain research customers. Demand for the NovaSeq X remains elevated, especially among some of our largest clinical customers, with we saw several multi-unit capacity expansion orders. This is a testament to the value of our customers' place on the Illumina ecosystem today and for years into the future.
Sequencing service and other revenue of $158 million was up 8 % on a rest-of-world organic basis. As Jacob mentioned in his prepared remarks, we are gaining traction in our billion-cell Atlas program as we continue to deliver data, converting more of our backlog to revenue. The pipeline and interest in our programs is very strong. Microarrays and other revenue of $110 million was up 2 % on a rest-of-world organic basis and included SOMA logic revenue that outperformed our initial deal model.
Moving to the rest of the P &L. Gross margin of 69.4 % was up 20 basis points year over year. Operating margin was 25 % for the quarter, 100 basis points above our guidance driven by higher revenue and disciplined investments. EPS of $1.44 per diluted share came in above the high end of our guidance range and was up 7 % versus Q3 of last year. Year-to-date, EPS is up 12 % versus 2025.
Moving to cash flow and the balance sheet, our cash flow from operations was $419 million and we generated $378 million of free cash flow in the quarter. We repurchased $9 million worth of stock in the quarter and at quarter end, we had approximately $1.8 billion remaining under our current share repurchase authorizations and we intend to continue to repurchase shares opportunistically. We ended the quarter with approximately $1.34 billion in cash, cash equivalents and short-term investments, $1.79 billion in total debt and a leverage ratio of approximately 1.4 times gross debt last 12 months EBITDA.
Overall, we had a great third quarter, allowing us to raise our full year guidance and reinforce our confidence in the progress we are making towards our financial targets. Now turning to our full year 2026 guidance, starting with revenue. We are raising our revenue guidance by $30 million at the midpoint to $4.64 to $4.66 billion. This reflects our Q3 outperformance and increased expectations for sequencing consumable sales in the fourth quarter. We still expect rest-of-world organic growth greater than 5%.
Product revenue guidance ranges are unchanged and we expect rest-of-world organic sequencing consumable growth of mid-single digits and low-single-digit instrument growth in 2026. We now expect operating margins of approximately 23.6 % at the high end of our previous guidance. With our higher revenue expectations for the year, this equates to diluted EPS guidance of $5.40 to $5.45, an increase of $0.08 at the midpoint versus our prior guide, and represents year-over-year growth of 12 % to 13%.
For our fourth quarter of 2026, we expect revenue of $1.22 to $1.24 billion and rest of the world organic growth of approximately 4.5%, similar to Q3. And we expect ETFs of $1.51 to $1.56 and operating margin of approximately 25%. We have made tremendous progress this year. adoption of sequencing across a wide range of clinical applications continues to grow and a rapidly growing X install base provides for a strong consumables revenue stream for years to come.
Revenue and customer interest in our billion-cell atlas are both expanding and we're just getting started on the large AI-based predictive biology opportunity that lies ahead. and our strong balance sheet and cash flows give us the flexibility to invest in areas of strategic growth that complement our innovative tool set. We are excited about our long-term outlook. In closing, I want to thank the Illumina team for their continued focus and disciplined execution throughout the year.

**Conor McNamara (Investor Relations)** [0:18:56]
Thank you for joining our call today and now invite the operator to open the line for Q &A.

**Operator** [0:19:02]
Thank you. At this time, if you would like to ask a question, please click on the raised hand button, which can be found on the black bar at the bottom of your screen. To give as many analysts as possible the opportunity to ask a question, please limit yourself to one question. If you have additional questions, please raise your hand again to be put back into the queue.
We will now pause a moment to assemble the queue. Thank you. Our first question is from Tyjo Peceson, from Jefferies. Please unmute your line and ask your question.

**Tycho Peterson (Jefferies)** [0:19:35]
Hey, thanks, guys. I want to pull up a little bit on the clinical considerable numbers. So, first of all, any stocking orders to call out? You had that last quarter, obviously. And then 4Q implies, I think, a little double-digit clinical growth. Is that the right jumping-off point as we think about next year?

**Jacob Thaysen (CEO)** [0:19:54]
Thanks, Tycho. And first and foremost, we continue to be pleased with the overall clinical performance. We see ourselves the full year in the mid-teens. we had here Q3 looked very much like Q2 with a 14-15 % growth in clinical and we continue this to expect that to continue. We will serve our customers, continue to serve them. They always put the text in the corner, but we feel good about how we see also Q4 coming along.

**Tycho Peterson (Jefferies)** [0:20:26]
Okay. And then obviously... Go ahead.

**Ankur Dhingra (CFO)** [0:20:29]
Tycho, to your question on the Q4, so overall, let's say I'm raising the guidance for Q4 consumables, our expectations that are going up given the strong placements that we continue to have. In terms of the growth rate question, I'll recall last year Q4 was a 11 % growth rate quarter on the sequencing consumables. So we're still expecting a pretty good 5-6 % growth in Q4. Overall, for the consumables, so that's still a good growth on top of one of the more unique compares throughout last year.
So that would be one of the factors there. But our expectations are improving for Q4.

**Operator** [0:21:15]
Our next question is from Vijay Kumar from Evercore ISI. Please unmute your line and ask your question.

**Vijay Kumar (Evercore ISI)** [0:21:21]
Hi Jacob and Ankur. Thank you for taking my question. I guess I have a two-parter, if you will. Your Q4 jump off here, I think it implies something close to 6 % for the rest of the world. And my question is, with that being the jump off, what's the right framework for 27?
Are the LRP targets still intact? And it's just given a strong instrument placement so far. Could instruments become a headwind next year? How do you offset it?

**Jacob Thaysen (CEO)** [0:21:52]
BJ, thanks for that. I can't believe you had to go into question number two before. We had a question about 27 here, but let me share a few points here. First and foremost, we will come out with a full guide in our Q4 earnings call. We've got to wait with the details.
But we are still operating in very healthy market environments, especially the clinical market is strong and we anticipate that clinical will be a growth driver for the company for the foreseeable future on top of that there is now also opportunities in what we are seeing with our multi-omics capabilities especially when the research market is coming back we're very well positioned for for taking advantage of that and on top of that the ai market it's just we're just scratching the surface on that but there's no doubt there is there is a substantial requirement and need for large data sets to really train models.
We can talk more about that later also. So that's the overall framing for how we see the future. One of the really worth is that, and how I think about the next year is that we have over the last quarters in this year, each quarter we have been growing our consumers above 5%. So we think that that's a good starting point here. We also see ourselves of course with what we talked about when we put the study in place in 2024, is that we see ourselves starting to move ourselves into growth, and the main driver was that we would make the X transition, thereby also lapse the price impact of that.
We are definitely on the latter end of that as Ancors spoke to in the prepare for marks. And then what we are seeing with the elevated placements of X is that that will of course continue to be a driver also for the growth. So that's how we think about it right now. I'll leave you with that.

**Operator** [0:23:50]
Our next question is from Doug Shenko from UBS. Please unmute your line and ask your question.

**Doug Shenko (UBS)** [0:23:56]
Good afternoon, and thank you for taking my questions.
Regarding MovaSeq X demand, you've had several quarters of solid X placements now, you know, above 80 this quarter. Are you seeing any indication that recent strength reflects pull forward in terms of what you might have expected in the future versus last quarter and this quarter? Or is the sustainability of the purchasing cycle still pretty strong right now? And building off of that, how would you characterize the mix of demand this quarter between capacity expansion tied to clinical volume growth versus transitions and replacements?
Thank you very much.

**Jacob Thaysen (CEO)** [0:24:40]
Thanks, Doc. First and foremost, I don't think there was any pull forward. I think this is a normal course of business. But overall, as I also mentioned, we are very pleased with the placements we have done over the last four quarters, which was outperformed the first year of X placements when we launched. And it really speaks to a few things. It speaks to that, as I mentioned also, the market conditions we are in and the opportunity, especially in the clinical space, is very healthy.
And the new assays that it's putting in place are very sequencing intensive. I think we haven't even seen what is coming. There's a lot more coming here. The intensity will continue to increase. So I think we will continue to see a strong demand for the X going forward. Secondly, as you probably recall, at AGBT, we were out showcasing the innovations that we bring to the X platform. So I also think that our customers are seeing that this is the platform to bet on for the future and much more innovation come out both in terms of quality of sequencing, but turnaround times and capacity of sequencing.
plus all the multi-omics assets that's coming on. So we feel good about where we sit and also for the future.

**Operator** [0:26:04]
Our next question is from Tuneet Souda from Learink. Please unmute your line and ask your question.

**Tuneet Souda (Learink)** [0:26:11]
Yeah, hi. Hi, I'm Jacob Brunker. Thanks for the question here. So just wanted to understand the dynamic on the sequencing consumable side. Is this a function of placing a number of instruments in the clinical space and applied in, obviously, research that is driving, you know, sort of a shift, you know, lower cost per gigabase, elasticity?
And that seems to be, you know, is that what's playing out here in the quarter? And then, you know, I just want to understand on 27, is the high single digit framework still intact? I just want to get your thoughts there.

**Jacob Thaysen (CEO)** [0:26:55]
Yes, I'm not sure I fully understand the first question on how the dynamic sequence consumables.

**Tuneet Souda (Learink)** [0:27:01]
Yeah, just in terms of are you seeing sort of a, you know, lower cost for gigabays from the labs coming to you essentially, you know, just because they are placing a new instrument that is providing them, you know, cheaper sequencing essentially right away in the first six months?

**Jacob Thaysen (CEO)** [0:27:24]
Well I think how we think about it obviously is that the transition from the 6K to the X that was a price step down obviously but also generated substantially more volume and that volume continues so it's not only a six month volume can be seen in the logic of a fixed budget but we actually do see that especially in the clinical space that we see that our customers, as we talked about before, are building bigger assays, also getting a better competitive positioning and continue to drive the growth and introduction or further advancement, especially in the oncology space of testing.
So I think that is playing out and that will continue to play out. So we feel good about how our growth is sitting with consumables and we think that's going to continue. I will say, of course, is that as many other companies, if you come to Illumina and are willing to sign up for a large volume, we, of course, are very willing to also talk about what the price point is for that. So that's the conversation I like to have with the customers.
If they come with you, as they would like to put in place that requires substantial more sequencing, we are absolutely more than willing to have that conversation and find how we both companies can be successful. That works well. From 27, as we mentioned, all the way back in 2024, is that our strategy is to walk ourselves or walk into growth. And we were predicting mid-single here for 25, and we still are on the track to deliver on the 27 of high single digits in that range.

**Operator** [0:29:13]
Our next question is from Sabu Nandi from Guggenheim. Please unmute your line and ask your question.

**Sabu Nandi (Guggenheim)** [0:29:20]
Hey guys, thank you for taking my question. I have a question. As the consumables, sorry, thinking ahead to 2027, I have two questions. First, do you still believe that new products have the potential to contribute one to two points of growth? Second, recognizing that you're going to exit 2026 at an operating margin of 25%, is that the right launch point?
Keeping in mind more progress towards operating improvement and improving mix as you move past pricing headwinds.

**Jacob Thaysen (CEO)** [0:29:51]
Yes, Rupu. So let me start with the first one. And just a reminder, we are still very much in Illumina operating in Q4. And we want to deliver Q4 before we go into details of 27. But I will say that what we talked about in 2014 about that we would add also a new growth driver through both our new assets that will come out and obviously also data is playing out well.
We have come out over the last 18 months with a very, very significant multi-omics portfolio and also with the acquisition of Somalogic, we're very well positioned in that space. And that has momentum, obviously from a low base, but this will start to actually reflect in our numbers both here in 26, but particularly in 27 and beyond. So we feel good about that. I think related to our operating margin, again, if you look over the last few years, we have increased or improved our margins to 400 basis points.
And I feel really good about what the team has achieved over the past years. We have had a lot of headwinds that we didn't anticipate, and I think the team has shown that we can deliver. This year, electronic component pricing, shipping costs, and obviously also some tariffs have been big headwinds. and we have been able to deliver expansion on margins. So I've been thrilled about where we are, and I think there is more to come in the years to come and also in 2017.

**Operator** [0:31:24]
Our next question is from Luke Sergot from Darkleys. Please unmute your line and ask a question.

**Luke Sergot (Darkleys)** [0:31:30]
Great, thanks. I was muted. I just wanted to follow up on the implied growth here of, you know, the exit rate on the clinical sequencing and how to think about when your next year, you've got all the liquid biopsy players, you're seeing a strong growth in all their samples, and then you have the conversion there from a lot of them converting to the X.
And so how does that play out with initial reads and concordance studies and then when that starts to flip on back onto the X?

**Jacob Thaysen (CEO)** [0:32:05]
Well, I think it is playing out as we expect. I mean, what we've been very pleased with over the last four quarters is the elevated placements of the X. And as you know, we are in a razor-blade logic in the company. So the more instruments we place, nobody buys an instrument to put in the corner.
They all put it there to generate more revenue. So obviously, every time we place an X, that is a revenue generator for the years to come. And so with that and with the elevated placement, we feel good about the growth opportunity in the consumables also for the years to come. As I mentioned before, the clinical market is very healthy. I know many of you want to sit and have a conversation about whether we grow 14%, 15 % or 16 % in clinical.
What the takeaway is that this is a strong market. There is still a lot of application that is just coming online. So we feel good about that and we see that that has legs. If you just look at it, a great point here is the U .S. CAN business that has continued to grow very, very strongly over the last four quarters in the clinical and we don't think that will stop.

**Ankur Dhingra (CFO)** [0:33:23]
Yeah, that's well covered on the clinical side.
Luke, to your point about the clinical, the only thing I would add is to look at the number of tests that have recently come on market, the volume growth of on market tests, and the number of clinical trials that are still expected to read out over the next one year, implying the new tests that would be coming to the market, and that's a very rich pipeline.

**Operator** [0:33:52]
Our next question is from Dal Narias from SIPO. Please unmute your line and ask your question.

**Dal Narias (SIPO)** [0:34:04]
Yeah, hi guys. Thanks for the questions here. Jacob, can you hear me?

**Jacob Thaysen (CEO)** [0:34:08]
Yes, go ahead.

**Dal Narias (SIPO)** [0:34:09]
Okay, thanks. Jacob, as you guys try to tap into this training model, virtual cell, AI opportunity, can you just talk about how you see genome pricing playing into that? I mean, obviously you think that the X is the box to bet on, but there are some pretty cheap genomes that are being talked about out there pushing down to 50 bucks. So to what extent do you think that you might need to revisit the price elasticity discussion in order to make sure that you really take those large projects?
Can you win those with the current pricing scheme, or do you think it takes whatever the new 35D flow cell might bring on genome cost?

**Jacob Thaysen (CEO)** [0:34:48]
Well, first and foremost, we're really good where we are. I think AI model is way beyond what a whole genome pricing. There's a lot going into this. So let me just try to frame this a little bit. First and foremost, I think we see a big opportunity in what I would call the predictive biology.
But if you want to step into that new logic of world, This could be very, very, have a substantial impact on everything we do both in our space, but if you think about life science as a whole, this could revolutionize our understanding on biology and it could definitely also have big disruption into overall the healthcare industry. This is where Lumina is very well positioned because it's not only about the price of sequencing It's about the ability to develop and create large data sets that goes across both the genome, the transcriptome, the methylome, and of course also the proteome.
Combine that together, look at that from above, the single cell, and also a spatial context. There's no other company in this industry that has the broad portfolio and also has the ability to create those data sets. we started with the 1 billion cell it's a great example of a functional data set that's not only looking at something in time but when you try to see what is happening to a cell when you change your up or down regulate the gene so I think these are types of the data sets that you want to look for so we feel good about where we are look Illumina has been in the world for many years to deal with elasticity.
We love elasticity. We can address any opportunity that we need to. And you see this market could be much, much bigger. We have both the capabilities, but also the innovation pipeline to be a very strong player on that. So both developing the data sets ourselves, but also looking at five-year that we together with our customers, we create datasets, our customers can add on to those datasets and we can create a bigger and bigger datasets for training those models.
So we're excited about that and I'm not super concerned about what others are doing right now.

**Operator** [0:37:11]
Thank you. Our next question is Kyle Nixon from Canaccord Genuity. Please unmute your line and ask your question. Carl Nixon from Canical Genuity, please unmute your line and ask your question. We'll go to our next question, which is Dave Westenberg from Piper Steinser. Please unmute your line and ask your question.

**Dave Westenberg (Piper Sandler)** [0:37:34]
Hey, thanks guys. Sorry to belabor the same clinical sequencing question, but I think we're all kind of trying you get at the same thing, clinical 70 % of consumables, and how fast can it grow to kind of get you into that long-term, high single-digit kind of growth rate.
So as we're looking at the Cigna Terras, the Shields, et cetera, we want to know, even in the X transition, what kind of pricing, like discounts or kind of thing, growth that you can get from these customers net of that discount as we get into the 27, 28, 29s, because we know you are kind of stuck on this X, But we also want to know, like, when we're looking at that 25%, 30 % volume kind of growth rate on that, you know, how much can Illumina continue to grow?
Because, you know, we are confident that you're going to get, participate. We just want to know in kind of the magnitude of that participation.

**Jacob Thaysen (CEO)** [0:38:35]
Thanks, Dave. That's very specific into where we could go pricing-wise. I would leave you with that is that, as I mentioned before, we work very closely with our customers. I think many of our customers are seeing, of course, opportunities to build bigger and bigger assays that go for therapy selection, MRD, and also, of course, now MSET coming alive.
So what we are seeing is that obviously we will continue to have conversations. We will continue to make sure that both we can grow in alignment with our customers. Because there might always be some certain difference between the different growth rates, but what we are taking away is that when our customers are growing, we will also grow in very healthy. So we believe there is more opportunities in that space. We think there is more growth opportunities for Illumina.
So I think we have proven over the last few quarters or few years that we can step back into growth. The conversation 18 months ago was very, very different. I think all of you were questioning whether we could grow at all. Now we sit with mid-single growth in consumables. Now you're questioning how much we can take that. I think you should see that we have a track record that shows that we can continue to expand our growth rate in those rates for consumables.

**Ankur Dhingra (CFO)** [0:39:54]
Yeah, one thing I would add there is that last quarter we added about the overall consumables growth rate in U .S. and Canada, which is a proxy of some of the customers that you were talking about. And within our US business, the growth rate within that clinical is well above the 14 % that you're talking about. So reasonably well indexed, that is. And always remember, the big customers make up a reasonable part of our business, but the luminous business is global.
And it both benefits, and otherwise, from the clinical activity across the world. Within our US business, that growth rate on the clinical is well above that 14%.

**Operator** [0:40:37]
Our next question is Kyle Mixon from Canaccord Genuity. Please unmute your line.

**Kyle Mixon (Canaccord Genuity)** [0:40:42]
Thanks, guys. Sorry about that before. Congrats on the quarter. I wanted to ask about a different way to ask about the 27 beyond, I guess. Congratulations on the kind of executing on the strategy day for 2024 sort of numbers and the framework and all that.
But, I mean, is there upside to the high single-digit growth going forward? I think obviously, as was discussed before, you got AI, multi-omics, maybe a research inflection, clinical, I feel like that could be kind of longer term as well. So could you approach double-digit growth perhaps while expanding operating margins for the high 20s and what could that take really?

**Jacob Thaysen (CEO)** [0:41:22]
Yeah, look, Kyle, I think, yeah, this is absolutely not impossible. I mean, there's definitely offsides to a high single-digit growth, but remember a few things here when we were laying out our strategy in 24 we were in a negative growth arena and now we have stepped ourselves into missing the growth i'm i think we want to
show we can do high single data before we go beyond that but but i i do i mean and we you can also see over the last few years there's been a lot of headwinds that this industry and and illumina specifically had to deal with uh you can pick your one you want to talk about but but there's been plenty so um we think that we are operating in a significant market opportunity space, particularly in clinical, and we think that it's going to continue to expand over the years.
We are very well positioned when the research segment is coming back with our multi-omics portfolio where we see a lot of brands being moving in that direction right now. And then of course the whole AI space where there will be substantial data sets generated and looked for. And I think that is something that when you, with our 1 billion seller atlas, shows that we are very well committed. It's not about just selling sequences anymore in that space.
Our customers and the broad spectrum of customers is looking for companies like Illumina that can actually generate those data sets. They're much more interested in what those data sets can generate on obviously the models that can, how they can perform rather than the sequencing itself. So we are very well positioned and there's certainly opportunities to grow beyond that.

**Operator** [0:43:06]
Our next question is from Dan Lennon from RBC. Please unmute your line and ask a question.

**Dan Lennon (RBC)** [0:43:14]
Thank you a bunch.
Jacob and Ankur, you talked a bunch about BioInsight. when would BioInsight become more visible in the P &L? Would that be as soon as next year, or is that a farther out event?

**Jacob Thaysen (CEO)** [0:43:32]
Yeah, so I think, first of all, we actually established BioInsight approximately a year ago, which was a combination of our software, which is actually doing extremely well also. and I think for those of you who visited our booth and at our symposium at ASST, we really presented how important software is for the ecosystem.
So very excited about that. But we combined that with the data because there's a lot of synergies between the two. You have to generate data, but you also have to develop models on top of that. So as we mentioned in 24, the data and, of course, the multihomics business would start to generate 1 to 2% in the latter part so here in 27 of our strategic period when we look for 24 and that is playing out very well but i think you will depending on how that ai opportunity plays out which we actually are looks very very promising this could be substantially bigger but maybe anko you have a promise on that

**Ankur Dhingra (CFO)** [0:44:35]
yeah i think uh our view right
now is somewhere in 2027, there should be some sort of color that should be able to begin to add. The billion cell atlas and then the second sense we've talked about it expanding to 5 billion cells certainly would be one of the first drivers within that. Jacob mentioned we actually have a very broad set spectrum of customers in discussion about the cell atlas and several other new bioAI-based applications that they're working on. but we anticipate that somewhere in 2027, it does become more visible.
And the whole point around the new products and bioinsight adding one to two points of growth for 2027 would certainly be an area.

**Operator** [0:45:21]
Our next question is from Casey Woodring from JPMorgan. Please unmute your line and ask your question.

**Casey Woodring (JPMorgan)** [0:45:28]
Great, thank you for taking my questions. And I guess two just quick cleanups on 4Q. Could you quantify what the extra selling week means in terms of a tailwind to the quarter? And then are you expecting a budget flush?
So that's the first part. And then just there's been some noise this week on U .S. trade restrictions on some of your Chinese competitors. Meanwhile, you know, you guys are still dealing with China regarding the unreliable entities list. So just curious, has there been any change in your position with the Chinese authorities? And now that you've returned to growth year on year in the region in 3Q, what are you seeing on the ground with customer comfort given geophortical concerns?

**Jacob Thaysen (CEO)** [0:46:10]
Yeah, thanks, Casey. And first of all, we are, of course, very pleased to be back to growth in China. Our focus has been all the way through this time to work closely while our Chinese customer continues to drive innovation and obviously also work with the regulators in countries to make sure that we have a path for the future. We feel good. We are very committed to China and to serve our customers. We believe there's a huge opportunity there.
We learned about this situation as many of you did yesterday morning, and of course we are trying to better understand what the impact is. That's what I know at this point. From a budget perspective, budget-floss perspective, we are not anticipating any specific budget-floss besides what normal for Q4. Ankur, maybe you...

**Ankur Dhingra (CFO)** [0:47:01]
Yeah, let me cover the Q4 question there. Casey, so Jacob covered the budget flush side, so we haven't assumed anything meaningful there. So if there is indeed a stronger budget flush, that would be a potential upside into Q4.
Now, regarding your question about the extra week, let me contextualize that. So for everyone, So Illumina reports on a fixed number of weeks per quarter basis, usually, which means that once every four years, we end up with an extra week to complete the cycle and come back into a consistent 13-week cycle there. The extra week in Q4 has always been part of our guidance throughout this year. That extra week falls during the holidays and very early part of January.
So the actual impact on revenue is quite minimal. That's not the window where we see a lot of top line activity. So fairly minimal impact on revenue. On the expense side, of course, we have the cost of our people cost for one extra week. But both of those have been part of our guidance and thinking all throughout the year. And just to be clear, our raise of consumables expectations for Q4 is entirely from the strong placements and the customer demand that we've seen so far.

**Operator** [0:48:27]
Thank you. Our next question is from Dan Brennan from TD Cowan. Please unmute your line and ask your question.

**Dan Brennan (TD Cowen)** [0:48:34]
Great, thank you. Maybe just one on AI. I know there's been a lot of discussion there so far, but if we think about the next, say, three-plus years or so, is the opportunity more on the service side for Luminate through BioInsight, or is it going to be substantial or opportunity on the placing boxes in traditional flow cells.
I'm just wondering how that splits out. And then related to that, you know, you talk about the billion cell atlas. So is the way to think about it right now from what you're seeing in your pipeline and backlog, is it more going to be on single cell and multiomics versus traditional whole genome? And then a quick follow-up just on Nova X pricing in the quarter, just if you can give any color on that, that would be helpful.

**Jacob Thaysen (CEO)** [0:49:13]
Okay. So good question, Dan. I think how do you think about the AI opportunity as you mentioned? And the industry right now is looking for some huge data set that is both reproducible and standardized. And the problem is when you have individual PIs or individual postdocs or others that are sitting and building small data sets, these are quite noisy and it's very difficult for models to actually train well on those. we have seen many times that they are better in predicting where the data is coming from rather than predicting the biology that is that that what the uh what the the experiments were actually telling you so so that's what we're seeing a big demand uh and a big ask
for customers that would like us to help generate large data sets um that can help build those so because we can when we do those last data set obviously we also spend time on ensuring they're reproducible standardized and so on and I think so there's a big demand for that so there's certainly a huge opportunity for Illumina in what you can call in a service business format. At the same time we are of course in the business of placing instruments so you could imagine there's a lot of customers saying we can get access to the Illumina data sets can we augment that with our own data that we might want to keep to ourselves because of various reasons so I
think we'll see a lot of demand for that also so it would be a blend but versus how we traditionally think about it, we also think there's a big service opportunity. This plays extremely well to what Illumina, where we're sitting today. The capabilities we've built up over the last few years in this space is probably not fully understood but we have really become experts in how to think about or how to do perturbation for different cell lines and what it takes to build that quality and that's what some of our customers are really seeing a lot of benefits.

**Ankur Dhingra (CFO)** [0:51:13]
Yeah, let me add just a couple more things on the BCA and the way you think about it. Jacob covered it extensively. The power of our portfolio by having significant part of the multi-omics workflows is that the pathway where we stand today looks like combination of whole genome and proteomics, combination of single cell and transcriptomics, combination of spatial and transcriptomics. All of those combinations based on either specific organs where the research is or specific disease pathways where the research is happening.
So that combination of different multi-omics would vary, but that's what different types of data sets could be. As we've said, our billion-celled catalyst is a starting point, which is helping to causality in many areas already. but we do see a pathway for multiple combinations, as I was describing, of additional data sets that can be very meaningful and powerful going forward.

**Operator** [0:52:14]
Our next question is from Dave Westenberg from Piper Sandler. Please unmute your line and ask your question.

**Dave Westenberg (Piper Sandler)** [0:52:23]
Oh, whoops, I didn't even know I was going to be back on. Maybe I'll just ask a quick one on China. Did I see that, right, that was growth in the quarter? One was reported and one was REANX-7 and double digits. What happened there, I guess? And then secondly, how should we think about China on a go-forward basis? We obviously had the unreliable entity list, but we also didn't kind of expect that. And again, I'm sorry for that question.
I didn't even know I was going to be back on.

**Jacob Thaysen (CEO)** [0:52:53]
Dave, we always like to hear from you. So thank you for the decent question. I think, as I mentioned before, how to think about China is that we believe we have been committed, shown that we are committed to find a path forward in China. I think we have good relationships there. And the first and foremost, we are focusing on what we can control. And what we can control is to continue to support our customers, continue to drive innovations.
We see a lot of interest for a lot of our innovations in China, and we believe the opportunity in China is big. I think the Chinese customers want to see Lumina play in the market space, and we will continue to do our best to have a future in China.

**Operator** [0:53:40]
Our final question is from Tysha Peterson from Jeffries. Please unmute your line and ask your question.

**Tysha Peterson (Jefferies)** [0:53:48]
Hey, thanks for taking a follow-up. Ankur, you called out operating leases, more operating leases.
I understand that was in context of the research market, but can you maybe elaborate there and any chance it spills over at clinical?

**Ankur Dhingra (CFO)** [0:54:04]
Yeah, so a great question, Taito. Both the entire operating leases as well as re-agent clinical models, we have had them on the offer for a fairly long period of time, but the demand there has been growing, both in the research as well as for clinical customers as well. We haven't seen that a whole lot with our largest clinical customers who have been in extensive capacity expansion.
But when you look at the mid-size clinical laboratories all over the world, including in US and in Europe, that's where we've seen interesting demand pickup in that space. But that offering is available to all our customers globally.

**Operator** [0:54:45]
This concludes the Q &A section of the call. I would now like to turn the call back to Conor McNamara for closing the mark.

**Conor McNamara (Investor Relations)** [0:54:55]
Thank you for joining us today. A replay of this call will be available in the Investor section of our website.
This concludes our call and we look forward to seeing you at upcoming events.
